Novavax (NVAX) Convertible Debt (2016 - 2025)

Novavax's Convertible Debt history runs 10 years deep, the most recent figure standing at $244.2 million for Q4 2025.

• In Q4 2025, Convertible Debt rose 43.92% year-over-year to $244.2 million; the TTM figure through Dec 2025 stood at $244.2 million (up 43.92% YoY), while the FY2025 annual figure was $244.2 million, up 43.92% from the prior year.
• Convertible Debt was $244.2 million for Q4 2025 at Novavax, roughly flat from $243.8 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $323.8 million in Q1 2022 to a low of $166.5 million in Q4 2022.
• Historically, Convertible Debt has averaged $219.8 million across 5 years, with a median of $169.9 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Convertible Debt slumped 48.54% in 2022, then soared 44.06% in 2025.
• A 5-year view of Convertible Debt shows it stood at $323.5 million in 2021, then tumbled by 48.54% to $166.5 million in 2022, then gained by 0.93% to $168.0 million in 2023, then increased by 0.99% to $169.7 million in 2024, then surged by 43.92% to $244.2 million in 2025.
• The last three Convertible Debt figures came in at $244.2 million (Q4 2025), $243.8 million (Q3 2025), and $170.6 million (Q2 2025), per Business Quant data.